Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Core Insights - Vera Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases [3] - The company will present at the TD Cowen Immunology & Inflammation Summit on November 13, 2025, and participate in one-on-one investor meetings [1][2] Company Overview - Vera Therapeutics' mission is to advance treatments targeting the source of disease to change the standard of care for patients [3] - The lead product candidate, atacicept, is a fusion protein administered at home as a subcutaneous injection, designed to block BAFF and APRIL, which are involved in autoimmune diseases like IgAN and lupus nephritis [3] - The company is also evaluating atacicept for additional diseases where reducing autoantibodies may be clinically meaningful [3] - Vera Therapeutics holds an exclusive license for VT-109, a next-generation fusion protein targeting BAFF and APRIL, with potential across various B-cell-mediated diseases [3] - Additionally, the company is developing MAU868, a monoclonal antibody aimed at neutralizing BK virus infections, particularly in kidney transplant recipients [3] - Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868 [3]